Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Codexis, Inc. - Common Stock (NQ: CDXS )

4.760 -0.230 (-4.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Codexis, Inc. - Common Stock

< Previous 1 2 3 Next >
Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
CDXS Stock Earnings: Codexis Misses EPS, Beats Revenue for Q2 2024
CDXS stock results show that Codexis missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
CDXS Stock Earnings: Codexis Beats EPS, Beats Revenue for Q1 2024
CDXS stock results show that Codexis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Recap: Codexis Q4 Earnings
Via Benzinga
Recap: Codexis Q1 Earnings
Via Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Codexis Clinches Deal With Nestlé Health Science, Eyes Up To $45M Milestone In EPI Treatment Breakthrough
Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI).  
Via Benzinga
“Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally”
Via AB Newswire
Exposures COVID-19
Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors. Nxu, shares rose 42.1% to $0.0278 in pre-market... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
3 Synthetic Biology Stocks Likely to Mint New Millionaires
Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks. 
Via InvestorPlace
The Next Nvidia: 3 AI Stocks That Could Break New Records
While trying to find the next Nvidia is a wildly risky proposition, these AI stocks to buy could be your ticket to extraordinary gains. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M
Via Benzinga
Topics Earnings
Exposures Financial
Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Codexis' Strategic Focus: Discontinues Biotherapeutics Development, Lays Off 25% Of Employees, Cash Runway Into Mid-2026
Codexis Inc (NASDAQ: CDXS) intends to prioritize advancing and commercializing its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis platform and its  
Via Benzinga
Cathie Wood's Ark Invest Makes Major Quantum-Si Purchase — Loads Up On 1.4M Shares Of Semiconductor Firm
Via Benzinga
Cathie Wood's Ark Invest Continues Tesla Selling Spree Despite Stock's Rise, AI Potential
Via Benzinga
Time to Evolve: 3 Synthetic Biology Stocks to Sell Off Now
The biotech boom has become a biotech bust. Many companies still have further to fall, so sell these three before they hit rock bottom. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2023
Via Benzinga
Codexis Shelves Development Of Certain Internal Programs, Cuts Workforce
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.